United States on RYGB may reduce diabetes risk factors

Recent studies have shown that Roux-Y gastric bypass surgery (RYGB) can quickly reduce the hyperglycemia associated with type II diabetes. Indeed, to accept RYGB obese diabetic patients even before their weight loss can often stop taking their medication. However, mechanisms to achieve reversal of diabetes in these patients has been unclear.

It was suggested, RYGB may cause intestinal hormone cycle - that is, change those in the brain have been told to eat after eating hormone.

However, in this report, the researchers introduced a related RGBY is how to induce a beneficial efficacy in diabetic patients a new perspective. In doing RYGB surgery, the stomach is divided into an upper portion of the assembly is small food pouch and a large number of the lower portion of the food can no longer build the pouch. Only a small pouch and the lower part of the intestine - specifically, small intestine - connected. However, the small intestine first surgical approach to what is known as "Roux loop" Y-type rearrangement.

Some recent studies in rodents and humans showed that after the RYGB procedure, Roux loop will experience a change in size will be extended. Growth in this sense is not clear.

The researchers assumed that build Roux loop and the morphological changes they experienced on blood glucose in patients with diabetes reduce RYGB has a direct role in suggesting undigested food will enter it, trigger it extended, while Roux loop through uptake of glucose and gather energy to sustain this expansion, so that glucose in the blood leaving fewer. This process represents a reprogramming of glucose metabolism, which is a loop structure in terms of Lu's unique process.

To test their hypothesis, the researchers in obese rats did Roux loop RYGB surgery and RYGB treated rats in the control group of rats with metabolic profile corresponding bowel metabolic activity were compared.

They found that the intestinal glucose RYGP treated rats in a way that would be like in a non-diabetic patients with metabolic; it will enter into the decomposition pathways capable of producing the desired tissue expansion matrix. But in the intestine without transformation of the control group of rats is not the case, these rats glucose will stay in the blood.

These findings confirmed the researchers' hypothesis that RYGB beneficial effect on diabetic patients due to change in the Roux loop glucose metabolism. ( Rat Free Thyroxine ELISA Kit http://www.cusabio.com/ELISA_Kit-79272/ )

However, if that is the case, these findings may give new diabetes treatment, paving the way, that is, by changing the intestinal metabolism that occur after RYGB to replace the use of invasive gastric bypass surgery methods.